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Background: The nucleotide-binding leucine-rich repeat (NLR) family of innate immune genes are important regulators of
inflammatory responses in mammals.
Results: The NLR gene, Nlrx1, suppresses neuroinflammation in vivo and inhibits microglial (Mg) activation.
Conclusion: NLRX1 immunosuppressive function in Mg correlates with suppression of neuroinflammation during mouse
models of Multiple Sclerosis (MS).
Significance: NLR genes can have protective roles during neuroinflammation.
The nucleotide binding domain and leucine-rich repeat-con-
taining (NLR) family of proteins is known to activate innate
immunity, and the inflammasome-associated NLRs are prime
examples. In contrast, the concept that NLRs can inhibit innate
immunity is still debated, and the impact of such inhibitory
NLRs in diseases shaped by adaptive immune responses is
entirely unexplored. This study demonstrates that, in contrast
to other NLRs that activate immunity, NLRX1 plays a protective
role in experimental autoimmune encephalomyelitis (EAE), a
mouse model for multiple sclerosis. When compared with wild-
type controls, Nlrx1/ mice have significantly worsened clini-
cal scores and heightened CNS tissue damage during EAE.
NLRX1 does not alter the production of encephalitogenic T cells
in the peripheral lymphatic tissue, but Nlrx1/ mice are more
susceptible to adoptively transferred myelin-reactive T cells.
Analysis of the macrophage and microglial populations indicates
that NLRX1 reduces activation during both active and passive EAE
models. This work represents the first case of an NLR that attenu-
ates microglia inflammatory activities and protects against a neu-
rodegenerative disease model caused by autoreactive T cells.
Multiple sclerosis (MS)5 is an autoimmune disease that pri-
marily affects adults between 20 – 40 years of age (1). In this
disease, T cells infiltrate and induce inflammation within the
CNS. The enhanced inflammatory environment in the CNS
contributes to neuronal demyelination and axonal damage.
Neuronal pathology causes the physical and mental disabilities
associated with MS. The mouse model of experimental autoim-
mune encephalomyelitis (EAE) mimics many aspects of MS and
has led directly to the development of several therapeutic treat-
ments (2). As with MS, the characteristics of EAE include T cell
immune responses to myelin antigens, neuronal pathology, and
CNS inflammation.
The nucleotide binding domain and leucine-rich repeat-con-
taining (NLR) protein family consists of intracellular sensors
that regulate inflammatory responses (3). Previous studies have
shown that NLRs and their adaptors can positively influence
the development of EAE (4 – 6). Deletion of the “inflam-
masome” Nlrp3, the adaptor-encoding Asc, or the caspase-1
gene resulted in better clinical outcomes. ASC and Caspase-1
have been shown to influence the production of encephalito-
genic T cells in lymphoid tissue, mostly by influencing the
expression of IL-1 and IL-18 (4, 5). NLRP3 has also been
shown to modulate worse outcomes in the EAE model by
enhancing T cell migration and TH1/TH17 development. Addi-
tionally, Nod1 and Nod2 contribute to pathogenesis in EAE by
regulation of CNS-infiltrating dendritic cells (12). These find-
ings collectively demonstrate that NLR proteins and adaptors
can exacerbate EAE.
Although NLRs have been shown to be important in periph-
eral myeloid monocytic cells, their roles in microglia (Mg) are
less studied. Mg are the chief immune cells in the CNS and have
important roles in numerous neurodegenerative diseases.
Microglial activation results in cytokine/chemokine secretion,
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induction of MHC class II molecules, and production of nitric
oxide. Pharmacological targeting of microglia has been demon-
strated to suppress the clinical symptoms of EAE (7, 8).
Additionally, Mg become activated and promote neuroinflam-
mation during the EAE model as well as in MS patients (9).
Therefore, Mg-mediated CNS inflammation is significant in
the context of both EAE and MS.
NLRX1 is a mitochondrially localized NLR protein (10) that
has been characterized as a non-inflammasome NLR because it
does not affect IL-1 production (11). Previous studies have
demonstrated that NLRX1 functions to repress inflammatory
responses to microbes (10, 11). Recent work increasingly rec-
ognizes the significance of innate immune sensors/receptors in
“sterile inflammation,” defined as inflammation that occurs in
the absence of an obvious pathogen (12). Inflammation in the
CNS can fall into this category and occurs in diseases with
immunologic associations, such as MS as well as those without
an immunologic cause such as Alzheimer disease and Parkin-
son disease. In this work, we demonstrate that NLRX1 func-
tions as a protective factor against EAE by suppressing CNS
inflammation and macrophage/microglial activation. This is
the first report of an NLR that functions to repress inflamma-
tion and protect against neurological disease.
EXPERIMENTAL PROCEDURES
Mouse Generation—The Nlrx1/ mice were generated as
described previously (11). 2D2 Tg mice (13) were purchased
from The Jackson Laboratory. All mouse studies were used in
accordance with the National Institutes of Health Guide for the
Care and Use of Laboratory Animals and Institutional Animal
Care and Use Committee guidelines of the University of North
Carolina Chapel Hill.
Active Induction of EAE—Induction of EAE was performed as
described (14). Briefly, MOG(35–55) peptide (Genemed Syn-
thesis Inc.) was emulsified in complete Freund adjuvant and
mixed with a Luer lock syringe system (Cadence, Inc). The dos-
age of heat-killed Mycobacterium tuberculosis in the emulsion
was 4 mg/ml. The emulsion was subcutaneously injected to
sites adjacent to the mouse tails. For the experiment depicted in
Fig. 1A, 200 ng of pertussis toxin was injected intraperitoneally
at 0 and 2 days post-immunization. For Fig. 1B, 100 ng of per-
tussis toxin was injected at 0 and 2 days post-immunization.
The following scale was used to assess clinical scores: 0, normal
mouse, no overt sign of disease; 0.5, partial tail paralysis (loss of
tip tail tonus); 1, limp tail or hind limb weakness but not both; 2,
limp tail and hind limb weakness; 3, partial hind limb paralysis;
4, complete hind limb paralysis; and 5, moribund state, sacrifice
for humane reasons. Animals were scored by two independent
investigators. All additional experiments describing the active
EAE model were performed under the conditions depicted in
Fig. 1A.
Real-time PCR Analysis—Total RNA was extracted from the
spinal cord using TRIzol (Invitrogen). cDNA synthesis was per-
formed using a reverse transcriptase kit (Promega). RNA accu-
mulation was measured using TaqMan primers against various
inflammatory mediators. The accumulation of inflammatory
mediators was determined on the basis of actin expression, and
levels of inflammatory mediator expression was determined
by a standard Ct method. Actb (Mm00607939_s1), Ifngr-
1(Mm00599890_m1), Il-17a (Mm00439618_m1), Cxcl10
(Mm00445235), Nlrx1 (Mm00617978_m1), Tnfa (Mm00443260_
m1), Il-1b (Mm01226189_m1), Ccl2 (Mm00441297_m1),
Il-12a (Mm00434165_m1), Il-17f (Mm00521423_m1), Gm-
csf (Mm01290062_m1), Il-22 (Mm01226722_g1), Il-23a
(Mm00518984_m1), Il-6 (Mm00446190_m1). Il-4 (Mm00445259_
m1), and Il-13 (Mm00434204_m1) were used.
Immunoblot Analysis—Analysis was performed with either
the indicated cell or spinal cord lysates using antibodies against
NLRX1 (15), myelin basic protein (Santa Cruz Biotechnology,
catalog no. sc-13914), glial fibrillary acidic protein (Thermo
Scientific, catalog no. OPA1-06100), HSP90 (Santa Cruz Bio-
technology, catalog no. sc-7947), NOS2 (Millipore, catalog no.
NGY63), GST-Pi (Enzo, catalog no. ADI-MSA-102), GAPDH
(Cell Signaling Technology, catalog no. 3683S), and MHC class
II molecules (Millipore, catalog no. MAB222).
Immunohistochemical Analysis—Animals were perfused
with PBS and 4% formaldehyde (Sigma-Aldrich). Spinal cords
were embedded in paraffin and cut into 5-m sections. Myelin was
measured using a Luxol fast blue (LFB) periodic stain or a Luxol
fast blue-periodic acid-Schiff (PAS) base-hematoxylin stain.
Characterization of Inflammatory Cell Infiltration—Flow
cytometry with single cell suspensions from spinal cord tissue
(4) was performed with antibodies to detect CD11b (ebioscience,
catalog no. 15-0112-81), CD3 (ebioscience, catalog no. 11-0031-
82), CD45 (ebioscience, catalog no. 13-0451-81), CD4 (Biolegend,
catalog no. 100428), I-Ab (BD Biosciences, catalog no. 553552),
and CD39 (ebioscience, catalog no. 50-0391-80). Flow cytometry
analysis was performed on a CYAN flow cytometer.
Primary Glial Cultures—Primary glial cultures were gener-
ated following an established protocol (16), with differences in
microglia isolation. After 2.5 weeks in glial culture, Mg were
isolated using an anti-CD11b antibody fused with magnetic beads
(MACS). Mg were stimulated with Ultrapure LPS (Invivogen) (500
ng/ml) and IFN (Peprotech) (20 ng/ml). LPS and IFN were used
to stimulate Mg to induce both early (LPS, NF-B signaling) and
late (IFN, JAK/STAT signaling) signaling pathways for induction
of NOS2 and MHC class II molecule expression.
Intracellular Cytokine Staining—Single cell suspensions
were generated from the inguinal lymph nodes of mice 12 days
post-immunization. Cells were stimulated with 50 g/ml
MOG35–55 peptide for 48 h. Cytokine secretion was inhibited
with GolgiStop(BD) or GolgiPlug(BD) according to the instruc-
tions of the manufacturer. Cells were stained for CD3 (ebiosci-
ence, catalog no. 11-0031-82), CD4 (Biolegend, catalog no.
100428), CD8 (Biolegend, catalog no. 100714), IFN (Bioleg-
end, catalog no. 505826), or IL-17A (Biolegend, catalog no.
506964) and fixed in 1% paraformaldehyde. Flow cytometry
analysis was performed on a CYAN flow cytometer.
Adoptive Transfer of CD4 Encephalitogenic T Cells—The
passive transfer of EAE was performed as described previously
(17). Briefly, active EAE induction was performed in Tg 2D2
mice (13). 12 days post-immunization, CD4 T cells were iso-
lated from the spleen and draining lymph nodes using anti-
CD4 magnetic beads (MACS). 5  106 cells were transferred
intravenously to recipient mice, and pertussis toxin (200 ng)
was administered at days 0 and 2 post-CD4 T cell transfer.
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RESULTS
Nlrx1/ Mice Suffer Worse Outcomes during EAE—To test
whether NLRX1 has a role in EAE development, we immunized
WT and Nlrx1/ mice with MOG(35–55) peptide (see
“Experimental Procedures”) and evaluated the development of
limb paralysis. To minimize artifacts, Nlrx1/ mice were pro-
duced on a C57BL/6 genetic background, and the control mice
were bred in-house. Under a standard protocol, Nlrx1/ mice
suffered enhanced limb paralysis during both the acute and
chronic phases of EAE (Fig. 1A). Additionally, Nlrx1/ mice
suffered enhanced limb paralysis when using a lower dosage of
pertussis toxin (100 ng) (Fig. 1B). In both experiments, the
enhancement of limb paralysis in the Nlrx1/ mice was sus-
tained throughout the course of the disease (Fig. 1, A and B).
RNA analysis of spinal cord tissue revealed that Nlrx1/ mice
displayed enhanced expression of numerous inflammatory
cytokines and chemokines (Tnfa, Il-6, Il-1, Ccl2, Gm-csf, and
Il-12) during the acute stage of EAE (Fig. 1C). Analysis of the
chronic stage of EAE revealed sustained and even more sub-
stantial changes in the expression of inflammatory cytokines
and chemokines than the acute phase (Fig. 1D). These findings
collectively indicate that during EAE, NLRX1 suppressed dis-
ease symptoms and reduced the expression of inflammatory
cytokines and chemokines in CNS tissue.
Nlrx1/ Mice Suffer Enhanced Demyelination and Periph-
eral Immune Cell Accumulation during EAE—We next evalu-
ated the influence of NLRX1 on CNS damage during EAE.
Immunohistochemical analysis of spinal cord tissue revealed
that Nlrx1/ specimens exhibited enhanced demyelination, as
indicated by less LFB and more PAS staining in white matter
tissue (Fig. 2, A and B). Demyelination in the Nlrx1/ mice
was quantified by performing an immunoblot analysis for
FIGURE 1. Nlrx1/ mice suffer worse outcomes during EAE. A and B, clinical scores of WT and Nlrx1/ mice during EAE. n  8 per group (A) and 7(WT) and
10 (Nlrx1/) (B). The experiment in A was performed with 200 ng of pertussis toxin, whereas the experiment in B was performed with 100 ng of pertussis toxin.
All additional experiments describing the active EAE model were performed under the conditions used in A. C, real-time PCR analysis of various inflammatory
genes in spinal cord tissue at 14 dpi. n  6 (WT) and 7 (Nlrx1/). Relative expression levels were normalized to the WT (WT  1). D, real-time PCR analysis of
various inflammatory genes in spinal cord tissue at 63 dpi. n  5mice/group. Relative expression levels were normalized to the WT (WT  1). Error bars represent
mean  S.E. *, p 	 0.05.
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myelin basic protein in spinal cord tissues (Fig. 2C). Addition-
ally, LFB-PAS-hematoxylin staining demonstrated enhanced
immune cell infiltration into the spinal cord tissue of Nlrx1/
mice relative to the WT control (Fig. 2B). Flow cytometry
analysis of spinal cord tissue further showed that Nlrx1/
mice suffered enhanced accumulation of peripheral immune
cells (CD45high) cells in the CNS (Fig. 2D). Collectively, these
findings indicate that the worsened symptoms of the
Nlrx1/ mice during EAE correlated with enhanced demy-
elination and peripheral immune cell accumulation in the
CNS.
Encephalitogenic T Cell Accumulation in the CNS Is Height-
ened in Nlrx1/ Mice—We next evaluated whether NLRX1
influenced T cell development in the peripheral lymphatic tis-
sue. Flow cytometry analysis revealed that NLRX1 did not influ-
ence the frequency of CD4 and CD8 T cells within the drain-
ing lymph nodes (Fig. 3A, left panel). Additionally, intracellular
cytokine staining for IFN and IL-17A after restimulation with
the MOG peptide ex vivo demonstrated that NLRX1 did not
significantly affect the expression of either cytokine within
CD4 T cells (Fig. 3A, right panel). These results indicate that
NLRX1 did not significantly affect the production of patho-
genic TH-1 or TH-17 effector cells in the peripheral immune
system. Conversely, flow cytometry analysis revealed enhanced
accumulation of CD45high CD3 cells in the spinal cord tissue
of Nlrx1/ mice (Fig. 3B). Additionally, analysis of spinal cord
tissue revealed that Nlrx1/ mice had enhanced expression of
cytokine transcripts associated with inflammatory T cells,
including Tgfb-1, Ifn, Il-17a, Il-17f, and Il-22 (Fig. 3C). How-
ever, Il-23 expression was not increased, indicating that a global
gene induction did not occur (Fig. 3C). These findings collec-
tively indicate that NLRX1 represses T cell accumulation in the
CNS during EAE.
FIGURE 2. Nlrx1/ mice suffer enhanced CNS damage and peripheral immune cell accumulation during EAE. A, sections of lumbar spinal cord tissue
stained with LFB-PAS at 18 dpi. Top row, 100 magnification. Scale bars  100 m. Bottom row, 200 magnification. Scale bars  50 m. Arrows point to a lesion
in the white matter. B, sections of lumbar spinal cord tissue stained with LFB-PAS-hematoxylin at 18 dpi. Top row, 100 magnification. Scale bars  100 m.
Bottom row, 200 magnification. Scale bars  50 m. Arrows point to a lesion in the white matter that contains immune cell infiltrates. C, quantification of
demyelination by immunoblot analysis with anti-myelin basic protein (MBP) and anti-GAPDH antibody at 18dpi. GAPDH was used as a control for total protein
loading. The lanes represent individual mice. 4 mice/strain were tested. D, flow cytometric analysis of peripheral immune cell (CD45high) infiltration into spinal
cord tissue at 18 dpi. Left panel, contour map depicting the selection of the CD45high cell population. Right panel, total number of CD45high cells in the spinal
cord. FS, forward scatter (103). n  6 mice/group. Error bars represent mean  S.E. *, p 	 0.05.
FIGURE 3. Encephalitogenic T cell accumulation in the CNS is heightened
in Nlrx1/ mice. A, left panel, frequency of CD4 and CD8 T cell in the
draining lymph nodes during EAE at 12 dpi. Cells were gated on CD3 CD4
or CD3 CD8. n  6 mice/group. Right panel, intracellular cytokine staining
in CD3 CD4 T cells 48 h after stimulation with MOG(35–55) peptide. B,
analysis of T cell infiltration during active EAE. Left panel, contour map depict-
ing the selection of the CD45high CD3 population in spinal cord tissue. Right
panel, quantification of the CD45high CD3 cell populations in WT and
Nlrx1/ mice. n  6 mice/group. C, real-time PCR analysis of various inflam-
matory genes in spinal cord tissue at 14 dpi. n  6 (WT) and 7 (Nlrx1/).
Relative expression levels were normalized to the WT (WT  1). Error bars
represent mean  S.E. *, p 	 0.05.
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Nlrx1/ Mice Are More Susceptible to Adoptively Trans-
ferred Encephalitogenic T Cells—To directly address the impact
of NLRX1 downstream of encephalitogenic T cell production,
we performed adoptive transfer experiments with MOG(35–
55)-specific T cell receptor transgenic T cells isolated from 2D2 Tg
mice (13). After the transfer of encephalitogenic T cells into WT
and Nlrx1/ mice, the Nlrx1/ mice displayed enhanced limb
paralysis, disease incidence, and onset of disease symptoms (Fig.
4A). The worsened symptoms of the Nlrx1/ mice correlated
with a heightened accumulation of peripheral immune cells
(CD45high) in spinal cord tissue (Fig. 4B). Additionally, T cell infil-
tration into spinal cord tissue was enhanced significantly in the
Nlrx1/ mice (Fig. 4C). Because the same encephalitogenic T
cells were introduced into WT and Nlrx1/ animals, these find-
ings demonstrated that NLRX1-mediated protection occurred in
response to autoreactive T cells.
Peripheral Innate Immune Cells and Resident Microglial Pop-
ulations Are Hyperactivated in Nlrx1/ Mice during EAE—
To gain further insight into the influence of NLRX1 on the local
CNS environment, we evaluated the activation status of periph-
eral innate immune cells and microglia during both active and
passive EAE models by flow cytometric analyses. The activation
status of CD45high CD11b cells isolated from spinal cord tis-
sue was assessed by measuring the surface expression of the
MHC class II molecule I-A (18, 19). Typically, the CD45high
CD11b population is primarily comprised of macrophages/
monocytes but also includes dendritic cells and granulocytes.
Our results demonstrate that the presence of NLRX1 reduced
the expression of I-A on peripheral CD11b cells during both
active EAE and passive EAE (Fig. 5, A and B). Analysis of the
CD45low CD11b population cells in spinal cord tissue have
been used by many groups to identify CNS-resident Mg popu-
lations (8, 12, 18, 20, 21) (Fig. 5, C and D). Mg populations also
displayed a significant up-regulation of I-A expression in the
Nlrx1/ mice during active EAE (Fig. 5C) and after transfer of
encephalogenic T cells (Fig. 5D). Our results collectively dem-
onstrate that expression of MHC class II molecules on both
peripheral innate immune cells and Mg populations was
increased dramatically in the Nlrx1/ mice during both active
and passive EAE.
Nlrx1/ Microglia Have Enhanced Inflammatory Responses—
Examination of CNS tissue revealed that enhanced microgliosis
occurred in Nlrx1/ mice during both active and passive EAE
FIGURE 4. Nlrx1/ mice suffer worse outcomes in response to encepha-
litogenic T cells. A, clinical scores of WT and Nlrx1/ mice after transfer of
encephalitogenic T cells. n  9 mice/group. B, flow cytometric analysis of
peripheral immune cell (CD45high) infiltration into spinal cord tissue at 16 dpi.
Left panel, contour map depicting the selection of the CD45high cell popula-
tion. Right panel, total number of CD45high cells per spinal cord. FS, forward
scatter (103). n  5 mice/group. C, analysis of T cell infiltrates into spinal cord
tissue after encephalitogenic T cell transfer. Left panel, contour map depicting
the selection of CD45high CD3 cells. Right panel, total numbers of CD45high
CD3 cells in WT and Nlrx1/ mice. n  9 mice/group. Error bars represent
mean  S.E. *, p 	 0.05.
FIGURE 5. Peripheral innate immune cells and resident microglial popu-
lations are hyperactivated in Nlrx1/ mice during EAE. A, flow cytometry
analysis of CD45high CD11b cell populations in spinal cord tissue at 18 dpi
during active EAE. Left panels, contour maps depicting the selection of
CD45high CD11b cell populations. Center panel, I-Ab expression on CD45high
CD11b WT and Nlrx1/ cells. Right panel, mean fluorescence intensity (MFI)
was used to quantify surface expression of I-Ab. n  6 mice/group. B, flow
cytometry analysis of CD45high CD11b cell populations at 16 dpi during
passive EAE. The panels are the same as in A. n  5 mice/group. C, flow cytom-
etry analysis of microglia at 16 dpi during active EAE. Left panels, contour
maps depicting selection of CD45lo CD11b cell populations. Center panel,
I-Ab expression on CD45lo, CD11b WT, and Nlrx1/ cells. Right panel, mean
fluorescence intensity was used to quantify the surface expression of I-Ab. n 
5 mice/group. D, flow cytometry analysis of microglia at 16 dpi during passive
EAE. The panels are the same as in C. n  5 mice/group. Error bars represent
mean  S.E. *, p 	 0.05.
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(Fig. 6A). To further evaluate whether NLRX1 functioned
intrinsically within microglia, we prepared a standard glial cul-
ture from neonatal mice (16). Importantly, Nlrx1/ Mg pro-
duced more IL-6 and CCL2 after stimulation (Fig. 6B).
Enhanced activation of Nlrx1/ Mg was also demonstrated by
increased expression of NOS2 and MHC class II molecules (Fig.
6, C and D). Both NOS2 and MHC class II molecule expression
represent standard markers for microglia/macrophage activa-
tion (see below) (19). Collectively, our results demonstrate that
NLRX1 attenuates Mg activation both in vivo and in vitro.
DISCUSSION
EAE is a model for MS that represents a breakdown in immu-
nological tolerance. Unfortunately, the targeted tissue in these
disorders is the CNS, an area of the body that has a low toler-
ance capacity for damage (22). The CNS is initially attacked by
T cells that target CNS-derived antigens such as myelin pep-
tides. Antigen-presenting cells from the peripheral tissues play
an important role in this disease (4, 6). Additionally, Mg
respond to CNS damage and are the primary CNS-located cell
type that initiates inflammatory responses (1, 2). In the EAE
model, Mg activation precedes limb paralysis and high accumu-
lation of peripheral immune cell infiltrates (18). Therefore, Mg
are key players in maintaining CNS homeostasis after the initial
T cell-mediated damage. Our findings demonstrate that
NLRX1 represses excessive activation of innate immune cells
from the periphery and also Mg immune responses, both of
which contribute to CNS inflammation during EAE. Dysregu-
lated inflammatory responses in the Nlrx1/ mice are associ-
ated with exacerbated limb paralysis, tissue damage, and
peripheral immune cell accumulation into the CNS.
During EAE, the NLR family and adaptor components NLRP3,
ASC, Nod1, Nod2, and Caspase-1 have all been reported to exac-
erbate limb paralysis, inflammation, and CNS damage (4 – 6).
NLRP3 and ASC function in regulating cytokines that then pro-
mote the development of encephalitic TH-1 and TH-17 subsets
(4) and promote T cell migration (23). Nod1 and Nod2 have
been shown to regulate the activation of CNS-infiltrating den-
dritic cells (6). These studies indicate that the function of NLR
proteins in innate immune cells promotes worse outcomes in
the EAE model. In contrast to those findings, our work demon-
strates that NLRX1 represses disease progression. We show
that NLRX1 functioned in Mg to inhibit excessive production
of IL-6 and CCL2. IL-6 has a pathogenic role in EAE (24) and
promotes the survival of activated CD4 T cells, the recall
responses of memory CD4 T cells, and the migration of acti-
vated CD4 T cells to tissues (25). We also demonstrate that
NLRX1 inhibits the production of CCL2. CCL2 recruits
immune cells into damaged tissues (26) and promotes T cell
migration to the CNS during EAE (27). Our findings show that
enhanced expression of CCL2 in Nlrx1/ mice correlates with
heightened T cell infiltration into the CNS. Hence, in contrast
to other studies characterizing the function NLR proteins in
the EAE model, NLRX1 represses the activation of CNS-
infiltrating innate immune cells and CNS-resident Mg pop-
ulations to extrinsically modulate encephalitogenic T cell
activity. To this point, the passive transfer of encephalito-
genic T cells induced enhanced disease in Nlrx1/ mice,
indicating that NLRX1 functions to protect against autoreactive T
cells.
Although numerous studies have characterized the role of
the Toll-like receptor family in regulating Mg responses (28),
work with the NLR family of proteins has been more limited.
The inflammasome NLR protein NLRP3 and the NLR adaptors
ASC and Caspase-1 have been shown to positively regulate Mg
immune responses (29). Using microglial cell lines, it was dem-
onstrated that NLRP3 and ASC are required for IL-1 produc-
tion in response to amyloid- (29). Furthermore, it was shown
that Caspase-1 contributes to the production of chemokines
and neurotoxic molecules (29). NLRP3 has also been shown to
promote NOS2 expression and M1 status in microglia (30).
These results collectively demonstrate a pathogenic role for
NLRP3, ASC, and Caspase-1 in microglial inflammatory
responses. Our results provide the reciprocal finding that
NLRX1 represses the production of inflammatory cytokines/
chemokines, NOS2 accumulation, and expression of MHC
class II molecules. Mg activation provides for tissue defense,
whereas the subsequent alternative/deactivation states modu-
late tissue repair (19). We demonstrate that Nlrx1/ Mg have
enhanced expression of NOS2 and MHC class II molecules,
both of which are standard markers for Mg activation. There-
fore, our work is the first to demonstrate that an NLR protein
can inhibit Mg immune responses through regulating Mg acti-
vation status.
Almost all neurological disorders lead to acute inflammation,
in which microglia function to regulate tissue defense and
repair (31). Excessive activation of these cells promotes a
chronic, perpetual inflammatory cycle that ultimately results in
neurodegeneration (32). Our findings demonstrate that an NLR
protein can inhibit not only peripheral innate immune cells but
also Mg inflammatory responses and reduce CNS pathology
FIGURE 6. Nlrx1/ microglia have enhanced inflammatory responses. A,
top panel, total numbers of CD45lo CD11b populations in spinal cord tissue
18 dpi during active EAE. n  6 mice/group. Bottom panel, total numbers of
CD45lo CD11b populations in spinal cord tissue 16 dpi during passive EAE.
n  5 mice/group. B, ELISA analysis of cytokines and chemokines produced by
primary WT and Nlrx1/ microglia after stimulation with LPS/IFN. C, immu-
noblot analyses of NOS2 in primary WT and Nlrx1/ microglia after stimula-
tion with LPS/IFN. Actin was used as a total protein loading control. D, Immu-
noblot analyses of MHC class II molecule expression in primary WT and
Nlrx1/ microglia after stimulation with LPS/IFN. HSP90 was used as a total
protein loading control. Error bars represent mean  S.E. *, p 	 0.05.
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during EAE. Because the majority of therapeutic treatments for
MS are targeted to the peripheral immune system (33), a further
characterization of Mg activation in disease progression repre-
sents an understudied aspect of this disease. Additionally, Mg
activation and dysregulation of inflammatory responses are
hallmarks for numerous neurological diseases including Par-
kinson disease, Alzheimer disease, and amyotrophic lateral
sclerosis (31). Therefore, further studies elucidating the role of
NLR proteins in CNS inflammation should yield valuable
insight into the broader field of neurodegeneration.
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